Search 

Foucus on R&D Small moleculer anti oncology and inmuno-oncology.

Abbott Medicine Division

Pharma

We are a leading CRO biotech company. We focus on antibody development.

Able Cerebral, LLC (ACL) :
ACL is a bio-pharmaceutical and medical device company with patented (US & China) technologies and products.
We have achieved our first goal via BrainGlucoseTM by providing timed release of brain energy as circadian therapy to eliminate nightmares, night sweating, hallucinations, which have been saving lives and dignity of many early and mid-stage Alzheimer’s patients; and to help diabetics to avoid nocturnal hypoglycemia for better sleep and protection from seizures, coma or even death.
More excitingly, through communications with FDA and experts in biopharmaceutical fields, we are initiating for phase III clinical study inquiry for our delayed and sustained release of energy product as breakthrough new drug status for Alzheimer’s disease.
We are also looking for investment or partnership to advance our game changing technology product, a noninvasive medical device, AddMemTM, which will be also the world’s first ever product for memory consolidation and recovery.
ACL is also a licensed manufacturer for medical food in Pennsylvania.
Our product can be marketed in China through registration with Chinese FDA as “special medical formulated food”, or apply as a new drug.

We have a very unique T-cell engager Bi-specific antibody platform.

Our COVID-19 neutralization antibody project is in phae 2 clinical tiral.

We have about 10 different Bi-specific projects in pre-clinical stage focusing on oncology, autoimmune and ophthomology.

We are looking for China partners to codevelop the Bi-specific antibodies.

We are also raising the capital to set up the CHina subsidiary.

You can add my wechat: elite8800

Solopreneur. Addiction recovery. Interventions. Family assistance. Organization and HR mentorships.
Virtual meetings Host, Guest, Panelist, Master of Ceremonies.

Abveris is a Massachusetts-based company that provides industry-leading solutions for therapeutic and reagent antibody developements. We have built a strong reputation for our ability to deliver outstanding science. Based on our proprietary hyperimmune mouse models, DiversimAb mouse, and a Beacon-based single B cell screening platform, we have custom-built gene-to-antibody solutions to support development efforts for therapeutic antibodies against difficult targets such as GPCR, ion channels, glycan targets. Abveris is rapidly expanding its antibody discovery capabilities and geographical presence to work with more emerging biotech to discover therapeutics for novel targets.

Achelios Therapeutics, Inc., based in RTP Carolina, is a privately held specialty biopharmaceutical company whose core competency is the reformulation of non-steroidal anti-inflammatory drug (NSAID) molecules that have historically been used to treat pain and inflammation by topical application.
Our proprietary formulation allows for fast and enhanced delivery of active agents across human skin into subdermal tissues.
Achelios is currently developing:
OTC 1% diclofenac topical formulation for the treatment of pain and inflammation. Our product shows improved efficacy, better compliance, photoprotection, and dossing schedule vs. Voltaren® ANDA to be submitted in 4Q 2021.
The next product in development is a superior 3% diclofenac formulation being developed for the prescription market for acute and chronic pain. These product has demonstrated greater efficacy, safety and photostability vs. other topical gels available globally. Our product has also shown efficacy as an opioid-spearing agent in the treatment of pain.